Biblio Discovery — Demo Discovery Service

4 results for "Jane Meisel"

Showing 1–4 · 0.00 seconds · RSS

  1. Journal Article

    Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy?

    Caitlin Taylor; Jane Meisel; Kevin Kalinsky

    Therapeutic Advances in Medical Oncology, Vol. 14 · 2022 · English · DOAJ Scopus

    The treatment of hormone receptor-positive, HER2-negative breast cancer has become increasingly individualized, thanks to the development of genomic testing. Gene expression assays provide clinicians and patients with both prognostic and predictive information regarding breast cancer recurrence…

  2. Journal Article

    Wilms' tumor of the ovary

    Vinita M. Alexander; Jane Meisel; Shannon O'Brien et al.

    Gynecologic Oncology Reports, Vol. 19 No. C · 2017 · English · DOAJ Scopus

    Extrarenal Wilms' tumor of the ovary is a very rare tumor likely derived from embryonic mesonephros. We present the first reported case of a teratoid extrarenal Wilms' tumor of the ovary with a short review of the existing literature. In the case, a 26-year-old woman presented with back pain and…

  3. Journal Article

    Administration of trastuzumab deruxtecan in metastatic breast cancer patients with severe hepatic impairment

    Laura Sun; Gaybrielle Moore; Annalise Labatut et al.

    Current Problems in Cancer: Case Reports, Vol. 16 · 2024 · English · DOAJ Scopus

    Background: Trastuzumab deruxtecan (T-DXd) shows efficacy in HER2-positive and HER2-low metastatic breast cancer (MBC), but its safety in patients with hepatic impairment is unclear. Methods: We report three cases of MBC patients with significant liver dysfunction treated with dose-reduced T-DXd…

  4. Journal Article

    Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer

    Veronica Jones; Hongwei Holly Yin; Yate-Ching Yuan et al.

    Scientific Reports, Vol. 15 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Despite endocrine therapy (ET), approximately 20–40% of Stage I–III estrogen receptor-positive breast cancer (ER + BC) patients experience recurrence. Recurrence while on ET is indicative of ET resistance. This study aimed to identify differentially expressed genes (DEGs) associated with…